Physician profile
Abraham Mathew
NPI 1396753448
$8,068.95
in general payments reported to CMS, 2019-2025
25 companies · $604 in 2025
The $604 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,011 · 2020: $1,913 · 2021: $2,348 · 2022: $1,143 · 2023: $588 · 2024: $460 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,526.90 | 2019-2025 | |
| Esperion Therapeutics, INC. | $1,508.15 | 2020-2023 | Nexletol |
| Novo Nordisk INC | $1,229.47 | 2019-2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $507.34 | 2019-2024 | Livalo, Seglentis |
| Amarin Pharma, INC. | $441.72 | 2019-2022 | |
| Glaxosmithkline, LLC. | $431.84 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $359.84 | 2019-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.98 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $305.69 | 2019-2023 | Farxiga |
| Nestle Healthcare Nutrition INC. | $287.14 | 2021-2023 | |
| Amgen INC. | $217.61 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $208.86 | 2019-2021 | |
| Exact Sciences Corporation | $135.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $126.56 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $81.95 | 2024-2025 | Zenpep |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $74.00 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.82 | 2020-2023 | Cycloset, Xifaxan |
| Ironwood Pharmaceuticals, INC | $45.40 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.39 | 2022 | |
| Eisai INC. | $30.31 | 2020-2021 | |
| Dexcom, INC. | $20.62 | 2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $18.53 | 2019 | |
| Sanofi-Aventis U.S. LLC | $18.29 | 2019 | |
| Medtronic, INC. | $16.45 | 2021 | |
| Mylan Specialty L.P. | $14.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.